The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Kiniksa raised its 2025 ARCALYST net sales guidance to $625 million to $640 million, up from prior guidance of $590 million to $605 million. This reflects management's confidence in continued growth ...

TARRYTOWN, N.Y., Feb. 28, 2011 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that in a second Phase 3 study (PRE-SURGE 2) in gout patients initiating allopurinol ...

Regeneron announced that its Phase 3 study of Arcalyst (rilonacept injection) met its primary and secondary endpoints for the prevention of gout attacks. This trial, known as PRE-SURGE 1 (PREventative ...

(RTTNews) - Kiniksa Pharmaceuticals Ltd.'s (KNSA) flagship product Arcalyst has garnered widespread acclaim and acceptance since its launch in April 2021. With a growing adoption rate, the company has ...

Credit: Getty Images. Arcalyst is a weekly, subcutaneously-injected, recombinant fusion protein that blocks interleukin-1. The Food and Drug Administration (FDA) has approved Arcalyst ® (rilonacept) ...

CEO Sanj Patel highlighted that Kiniksa achieved $137.8 million in net product revenue for ARCALYST during Q1 2025, marking a 75% increase year-over-year. This success was attributed to robust ...

Tarrytown, NY (August 11, 2008) – Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the publication of the results of three studies which supported the U.S. Food and Drug Administration ...

Regeneron Pharmaceuticals saw its stock slip over the weekend after US regulators placed a question mark over the safety of Arcalyst in the gout setting. Regeneron Pharmaceuticals saw its stock slip ...

Kiniksa Pharmaceuticals International (NasdaqGS:KNSA) has launched Heart's Home, a direct to consumer campaign for ARCALYST. The initiative focuses on raising awareness of recurrent pericarditis and ...